With Carboxylic Acid, Ester Or Metal Salt Thereof Patents (Class 514/163)
-
Patent number: 8119618Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: March 11, 2009Date of Patent: February 21, 2012Assignee: The Board of Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20120022001Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.Type: ApplicationFiled: September 12, 2011Publication date: January 26, 2012Applicant: STABLE SOLUTIONS LLCInventor: David F. Driscoll
-
Publication number: 20120015912Abstract: The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.Type: ApplicationFiled: January 7, 2011Publication date: January 19, 2012Applicant: Action MedicinesInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Maria Luisa Krauel, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
-
Publication number: 20120015032Abstract: The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients.Type: ApplicationFiled: August 8, 2008Publication date: January 19, 2012Applicant: HANALL PHARMACEUTICAL COMPANY, LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Sang Ouk Sun
-
Publication number: 20120003314Abstract: A timed or delayed release oral composition delivery system for the treatment of colonic disorders and diseases is provided. According to one aspect, a delayed release oral pharmaceutical composition includes an active core comprising a therapeutically effective amount of 5-amino salicylic acid (i.e., mesalamine); a primary coating composition disposed around the active core, wherein the primary coating composition includes an enteric polymer; and a secondary coating composition disposed around the primary coating composition, wherein the secondary coating composition includes a ratio mixture of ethyl cellulose and hydroxypropyl methylcellulose.Type: ApplicationFiled: September 15, 2011Publication date: January 5, 2012Applicant: ROXANE LABORATORIES, INC.Inventors: Vinay H. SHUKLA, Eric M. SPILLER
-
Publication number: 20110301130Abstract: The invention relates to a topical gel composition for use in the treatment of actinic keratosis comprising (a) an active agent for treatment of actinic keratosis, (b) a keratolytically active agent, (c) a gel former, and (d) an organic solvent.Type: ApplicationFiled: June 29, 2009Publication date: December 8, 2011Applicant: ALMIRALL HERMAL GMBHInventors: Manfred Melzer, Carmen Matthies, Klaus Treudler, Christoph Willers, Henning Mallwitz
-
Publication number: 20110237555Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.Type: ApplicationFiled: June 6, 2011Publication date: September 29, 2011Applicant: Action MedicinesInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20110230816Abstract: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.Type: ApplicationFiled: August 31, 2010Publication date: September 22, 2011Applicant: TYCO HEALTHCARE GROUP LPInventor: Warren Copp-Howland
-
Patent number: 8017138Abstract: A method for the topical treatment of skin aging and acne and the improvement of skin appearance is disclosed. Compositions for use in this method and a kit containing such compositions are also disclosed. In some of the embodiments of the invention, either one, or both, of the acid composition and neutralizing composition useful in the method for the topical treatment of skin aging and acne and the improvement of skin appearance are of low viscosity. The compositions and methods are effective but gentle enough to be suitable for daily home use by the consumer.Type: GrantFiled: December 12, 2008Date of Patent: September 13, 2011Inventor: Dennis Gross
-
Publication number: 20110217252Abstract: It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite.Type: ApplicationFiled: November 5, 2009Publication date: September 8, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventor: Aleardo Koverech
-
Publication number: 20110178047Abstract: Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.Type: ApplicationFiled: December 29, 2010Publication date: July 21, 2011Applicant: MARTEK BIOSCIENCES CORPORATIONInventors: Linda Arterburn, William Barclay, Bindi Dangi, James Flatt, Jung Lee, Mary Van Elswyk
-
Publication number: 20110159048Abstract: The present invention relates to methods and compositions for reducing Distress Dysfunction by restoring and maintaining homeostatic balance in the neurotransmitter systems underlying the Stress Response and the experience of distress and hedonic tone. Distress Dysfunction refers to the experience of dysfunctional emotional and physical distress that interferes with the individual's quality of life and functioning.Type: ApplicationFiled: December 20, 2010Publication date: June 30, 2011Inventors: Steven Crain, William E. Crain, Stanley M. Crain, Michael Crain
-
Publication number: 20110152223Abstract: Disclosed is an agent for preventing/treating ANCA-related vasculitis and/or preventing the recurrence of ANCA-related vasculitis. Also disclosed is a therapeutic method using the agent. Specifically disclosed is a pharmaceutical composition comprising at least one member selected from the group consisting of eicosapentaenoic acid, a pharmaceutically acceptable salt thereof and an ester thereof as an active ingredient. The pharmaceutical composition is useful for the prevention of recurrence of ANCA-related vasculitis, the treatment of chronic ANCA-related vasculitis, and the prevention and treatment of rapidly progressive glomerulonephritis (RPGN).Type: ApplicationFiled: August 21, 2009Publication date: June 23, 2011Inventors: Junichi Hirahashi, Makoto Arita, Keiichi Hishikawa, Toshiro Fujita, Masanori Nakakuki
-
Publication number: 20110152222Abstract: The present invention relates to the use of a compound of Formula (I??) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of arthritis and pain.Type: ApplicationFiled: August 15, 2007Publication date: June 23, 2011Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego
-
Publication number: 20110151024Abstract: The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases.Type: ApplicationFiled: March 1, 2011Publication date: June 23, 2011Inventor: Alexander Mauskop
-
Publication number: 20110144055Abstract: The use of a pharmaceutical regimen to deter in an individual, as the individual ages, the development of a cardiovascular disease (CVD) or Alzheimer's disease or to treat an individual who has CVD or Alzheimer's, the individual ingesting on a daily basis a regimen comprising pharmaceutically effective amounts of magnesium salicylate and naproxen, the amount of the magnesium salicylate being no greater than about 260 mg, and also the use of a pharmaceutical regimen to treat an individual who has Type 2 diabetes, the regimen being ingested daily by the individual and comprising pharmaceutically effective amounts of at least one glucose-lowering drug and magnesium salicylate in an amount no greater than about 260 mg.Type: ApplicationFiled: September 4, 2009Publication date: June 16, 2011Inventors: Anthony I. Rozmanith, Jolan S. Rozmanith
-
Patent number: 7935689Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R3 and R4 together are alkyl having two or three carbon atoms; or R3 and R4 are the same as each other and each is methyl or ethyl; R5 is hydrogen or alkyl having from one to six carbon atoms.Type: GrantFiled: May 11, 2007Date of Patent: May 3, 2011Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel
-
Patent number: 7928092Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: GrantFiled: June 10, 2010Date of Patent: April 19, 2011Assignee: AGI Therapeutics Ltd.Inventors: John Devane, Jackie Butler
-
Publication number: 20110082119Abstract: A highly safe and effective prophylactic/ameliorating or therapeutic agent for NACH and the method for using the same are provided. A prophylactic/ameliorating or therapeutic agent for NASH containing a combination of at least one first ingredient selected from the group consisting of an ?3PUFA and pharmaceutically acceptable salts and esters thereof and at least one second ingredient selected from the group consisting of (a) a biguanide hypoglycemic agent, (b) a nonsteroidal anti-inflammatory drug, (c) a 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, and (d) an angiotensin II receptor blocker as the active ingredients; and its method of use.Type: ApplicationFiled: June 12, 2009Publication date: April 7, 2011Inventor: Takashi YANO
-
Publication number: 20110064683Abstract: Described are personal care compositions, comprising an aqueous dispersion comprising an ethylene acrylic acid copolymer and a least one cosmetically acceptable surfactant, emollient, or cosmetic active.Type: ApplicationFiled: September 15, 2010Publication date: March 17, 2011Applicants: Technology Corporation)Inventors: Susan L. Jordan, Tatiana V. Drovetskaya
-
Publication number: 20110064813Abstract: The invention relates to a compound and administration of the compound to mammals containing salsalate in a nanofied form to reduce inflammation. This compound and administration may be combined with caffeine, omega 3 fatty acids, sodium bicarbonate, and/or simvastatin to further benefit that administration.Type: ApplicationFiled: August 6, 2010Publication date: March 17, 2011Inventor: Charles Vaughn
-
Publication number: 20110052694Abstract: Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.Type: ApplicationFiled: August 31, 2010Publication date: March 3, 2011Applicant: ALLTRANZ INC.Inventors: Audra Lynn Stinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffery Lynn Howard, Dana Carmel Hammell
-
Publication number: 20110034425Abstract: This invention relates to a method of treating acute myelogenous leukemia with TPA along with Dexamethasone and choline magnesium trisalicylate.Type: ApplicationFiled: August 4, 2010Publication date: February 10, 2011Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventor: Roger Strair
-
Patent number: 7879827Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.Type: GrantFiled: February 10, 2009Date of Patent: February 1, 2011Assignee: Antibe Therapeutics Inc.Inventors: John L. Wallace, Giuseppe Cirino, Giuseppe Caliendo, Anna Sparatore, Vincenzo Santagada, Stefano Fiorucci
-
Publication number: 20110021468Abstract: This invention relates to methods for the treatment of atherosclerotic cardiovascular disease using a non-acetylated forms of salicylate, e.g., salsalate and/or trilisate.Type: ApplicationFiled: July 3, 2008Publication date: January 27, 2011Applicant: JOSLIN DIABETES CENTER, INC.Inventors: Steven Shoelson, Allison B. Goldfine
-
Publication number: 20100310650Abstract: A pharmaceutical composition for the oral administration of omega polyenoic fatty acids combined with one or more active principles incompatible therewith, is described; also described is a process for preparing said pharmaceutical composition.Type: ApplicationFiled: June 26, 2007Publication date: December 9, 2010Inventor: Roberto Valducci
-
Publication number: 20100311700Abstract: A transdermal preparation for external use which contains a photosensitive NSAID and a UV blocker having a high ability to migrate into the skin. Thus, it becomes possible to ensure, in a transdermal preparation for external use containing a NSAID, the inhibition of the onset of light-induced non-immunological or immunological skin symptoms by the above-described component.Type: ApplicationFiled: April 29, 2010Publication date: December 9, 2010Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Kazuhisa Yoshitake, Kenji Atarashi, Tetsuji Kuwahara, Koichi Ikesue, Michinori Sakai, Yoshiaki Hashimoto, Kiyomi Tsuruda
-
Patent number: 7825106Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.Type: GrantFiled: March 10, 2006Date of Patent: November 2, 2010Assignee: AGI Therapeutics Ltd.Inventors: John Devane, Jackie Butler
-
Publication number: 20100239552Abstract: This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier.Type: ApplicationFiled: March 16, 2010Publication date: September 23, 2010Applicant: GENMEDICA THERAPEUTICS SLInventors: Eric Mayoux, Luc Marti Clauzel, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Alec Mian
-
Publication number: 20100204188Abstract: The present invention provides combinations, for treatment of subjects suffering from or at high risk of developing diseases and disorders involving expression of peroxisome proliferator-activated receptors (PPAR). The combinations include abscisic acid and one other bioactive agent, which together provide synergistic effects toward treatment or blocking of development of the disease or disorder. In exemplary embodiments, a combination of abscisic acid and a thiazolidinedione (TZD) is provided for increased insulin sensitivity and improved (i.e., reduced) obesity-induced inflammation.Type: ApplicationFiled: January 28, 2010Publication date: August 12, 2010Applicant: Virginia Tech Intellectual Properties, Inc.Inventors: Josep BASSAGANYA-RIERA, Amir Guri, Raquel Hontecillas
-
Publication number: 20100196343Abstract: Accordingly, a need has arisen for improved compositions, methods, devices, and systems for skin care including, without limitation, topical compositions and phototherapy devices and methods. A skin care method may comprise, in some embodiments, contacting at least a portion of the skin of a subject with a homogeneous, stable, self-foaming composition, illuminating the at least a portion of the skin exclusively with light of a desired wavelength (e.g., from about 390 nm to about 430 nm, and contacting the at least a portion of the skin with an anti-oxidant serum composition.Type: ApplicationFiled: September 4, 2009Publication date: August 5, 2010Inventors: Michael P. O'Neil, Joel Rubin, Drake Stimson
-
Publication number: 20100189669Abstract: Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.Type: ApplicationFiled: January 25, 2010Publication date: July 29, 2010Inventor: Tomohiro Hakozaki
-
Publication number: 20100189761Abstract: Methods for prevention or treatment of capsular contracture following surgical implants and other fibrosis related conditions comprising applying a topical composition comprising a pharmaceutically acceptable keratolytic, a pharmaceutically acceptable protein denaturant, a hydrating agent, and combinations thereof are disclosed.Type: ApplicationFiled: November 12, 2009Publication date: July 29, 2010Applicant: J&E Solutions, LLCInventors: Jeanne V. FRIEDMAN, Elsa M. Raskin
-
Publication number: 20100184728Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention.Type: ApplicationFiled: June 13, 2008Publication date: July 22, 2010Applicant: THERAPEUTIC RESEARCH LLCInventor: Jay Pravda
-
Publication number: 20100184727Abstract: A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion.Type: ApplicationFiled: June 7, 2007Publication date: July 22, 2010Applicant: SUMMIT (CAMBRIDGE) LIMITEDInventors: Alan Geoffrey Roach, Paul Goldsmith
-
Publication number: 20100159035Abstract: The invention provides a therapeutic composition, simultaneously containing (1) at least one polar solvent, selected from the group of a short-chain mono-alcohol and a diol; (2) between about 2% and about 25% of at least two keratolytic agents; and (3) a therapeutically safe and effective concentration of a antifungal agent It further provides a kit, consisting of an occlusive device and a therapeutic composition, useful for treatment of fungal skin infection.Type: ApplicationFiled: April 10, 2007Publication date: June 24, 2010Inventor: Avner Shemer
-
Publication number: 20100158993Abstract: Topical alcoholic gel compositions are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compositions comprise a topically active drug, an alcoholic solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is attained without the need of a step for neutralizing the pH of the composition. Alcoholic and alcohol-free topical compositions comprising an NSAID prodrug are also disclosed. The compositions are particularly useful for the treatment of pseudofolliculitis barbae.Type: ApplicationFiled: December 21, 2009Publication date: June 24, 2010Applicant: ISW Group, Inc.Inventors: Monique Spann-Wade, Anthony Ward
-
Publication number: 20100159031Abstract: Compositions and methods for treating or preventing fungal infections of the nail are provided. The topical composition includes the use of chlorine dioxide, chlorite salts, benzoyl peroxide, an alpha hydroxy acid, antifungal and antibiotic agents. Also provided is a heat-generating device for use in treating at least one nail infected with fungus and a toe sock device.Type: ApplicationFiled: October 7, 2009Publication date: June 24, 2010Inventor: Karen C. Swenholt
-
Publication number: 20100092400Abstract: Provided, among other things, is a delivery module for water-based salicylic acid composition comprising: an aerosol delivery system; within the aerosol delivery system, the salicylic acid composition comprising 0.5% or more salicylic acid by weight, lipophilic component(s), and a frothing agent, the salicylic acid composition having a viscosity low enough to support aerosol delivery, and the salicylic acid composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery system, a propellant, wherein the salicylic acid composition is non-irritating and has a non-watery feel.Type: ApplicationFiled: October 15, 2009Publication date: April 15, 2010Applicant: QUINNOVA PHARMACEUTICALS, INC.Inventors: Mats Silvander, Jeffrey S. Day, Linda M. Mahoney, Christopher Nelson Hensby
-
Patent number: 7691832Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention contains N-acetylcysteine disposed in a pharmaceutically acceptable carrier for oral or rectal delivery for treating such inflammatory bowel diseases by topical application within the colon.Type: GrantFiled: February 2, 2006Date of Patent: April 6, 2010Assignee: The Board of Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20100063009Abstract: A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) at least one non-steroidal anti-inflammatory drug (NSAID) component; a pharmaceutical composition and a dosage form comprising such as combination, and a method of treating pain and/or ostheoarthritis in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to said mammal, in which component (a) may be administered before or after component (b), and in which components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: September 4, 2009Publication date: March 11, 2010Applicant: GRUENENTHAL GmbHInventors: Petra Bloms-Funke, Klaus Schiene
-
Patent number: 7638507Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: February 2, 2006Date of Patent: December 29, 2009Assignee: The Board of Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20090318394Abstract: Disclosed are compositions containing DHA and DPAn-6 and methods of administering and using the same to treat or prevent at least one symptom of inflammation or neurodegeneration or disease states associated with inflammation or neurodegeneration. Also discloses are compositions containing specific dosages and/or ratios of long chain polyunsaturated fatty acids that are particularly effective in reducing or preventing symptoms of inflammation or neurodegeneration.Type: ApplicationFiled: January 21, 2009Publication date: December 24, 2009Inventors: Julie Nauroth, Linda Mary Arterburn, Mary Van Elswyk
-
Publication number: 20090312292Abstract: The invention relates to anti-microbial compositions useful against a wide range of microorganisms undesirable on a wide variety of materials, including food, food contact and non-food contact surfaces, and surfaces in industrial, recreational, health care, and other institutional environments. More particularly, the anti-microbial compositions comprise peracetic acid in combination with a) citric acid or a salt and b) salicylic acid or a salt in aqueous solution.Type: ApplicationFiled: December 20, 2007Publication date: December 17, 2009Applicant: FMC CORPORATIONInventors: John M. Rovison, Donald Lapham, III, Shibu Abraham, Mary Homan
-
Publication number: 20090238763Abstract: The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes.Type: ApplicationFiled: January 9, 2009Publication date: September 24, 2009Inventors: Chongxi Yu, Lina Xu
-
Publication number: 20090203655Abstract: This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.Type: ApplicationFiled: February 3, 2009Publication date: August 13, 2009Applicant: Martek Biosciences CorporationInventors: Linda Arterburn, James Hoffman, Harry Oken, Mary Van Elswyk
-
Publication number: 20090202457Abstract: The present invention relates to an exfoliating composition. The composition comprises a mixture. The mixture comprises phenolsulfonic acid, guaiacolsulfonic acid, and optionally sulfosalicylic acid and citric acid.Type: ApplicationFiled: March 9, 2009Publication date: August 13, 2009Inventor: Michael Basara
-
Publication number: 20090192126Abstract: A composition which is adapted for oral consumption and which is in the form of a substantially homogeneous aqueous emulsion, suspension or dispersion comprising salicylic acid, or a C1 to C6 alkyl ester thereof, and docosahexaenoic acid (DHA) can exhibit an anti-inflammatory effect in skin.Type: ApplicationFiled: April 5, 2007Publication date: July 30, 2009Inventors: John Casey, Alexander Gordon James, Gail Jenkins, Linda Jane Wainwright
-
Patent number: 7544349Abstract: There are described personal care compositions containing a) one or more dibenzoylmethane sunscreening agents; and b) a photostablising amount of a salicylate ester of formula (1): (2-OH)Ph-(CO)—O—R, wherein R represents an alkyl group consisting of a chain of from 7 to 16 carbon atoms substituted by at least one group selected from methyl and ethyl. The compound of formula (1) is preferably isodecyl salicylate or isotridecyl salicylate. The salicylate esters of formula (1) have a stabilizing effect on the compositions. The salicylate esters prevent or inhibit degradation of the sunscreening agents which would otherwise lead to a reduction in the efficacy of the sunscreening agents and an increase in the deleterious effects of exposure to sunlight on the user of the compositions or on the compositions themselves.Type: GrantFiled: July 31, 2002Date of Patent: June 9, 2009Assignee: The Boots Company, PLCInventors: Jane Evison, Janet Palin, Edward Galley
-
Publication number: 20090124574Abstract: The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of a disorder associated with platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments. Further embodiments provide for pharmaceutical compositions that include one or more carotenoid analogs or derivatives in combination with one or more additional compositions or medicaments suitable for the treatment of a disorder associated with platelet aggregation.Type: ApplicationFiled: March 24, 2008Publication date: May 14, 2009Inventors: Samuel F. Lockwood, R. Preston Mason